B2M and chronic kidney disease: In our study, we identified seven promising biomarkers-BTP, Fetuin-A, Klotho, Uromodulin, ADMA, NGAL and B2M-that demonstrated significant diagnostic potential for distinguishing between CKD, AKI and healthy controls (Table-I).